**Core Concept**
The question is testing the student's knowledge of antiretroviral drugs that target specific co-receptors involved in HIV entry into host cells. **CCR2 and CCR5** are chemokine receptors that HIV uses to gain entry into host cells, and antiretroviral drugs that bind to these receptors can inhibit HIV entry.

**Why the Correct Answer is Right**
The correct answer is a drug that can bind to both CCR2 and CCR5. **Maraviroc** is a CCR5 antagonist that has been shown to bind to both CCR2 and CCR5, although its primary action is on CCR5. Maraviroc works by binding to the extracellular domain of CCR5, preventing HIV from binding and entering host cells.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it is not a known antiretroviral drug that targets CCR2 and CCR5.
* **Option B:** This option is incorrect because it is not a known antiretroviral drug that specifically targets CCR2 and CCR5.
* **Option D:** This option is incorrect because it is not a known antiretroviral drug that targets CCR2 and CCR5.

**Clinical Pearl / High-Yield Fact**
Maraviroc is a unique antiretroviral drug that targets the CCR5 co-receptor, but its binding profile is distinct from other CCR5 antagonists. This makes it a useful option for patients with certain genetic variations in the CCR5 gene.

**Correct Answer:** C. Maraviroc